ABT vs BTAI · P/E 25, rev $44.33B vs rev $388.0K
Abbott Laboratories (ABT) versus BioXcel Therapeutics Inc (BTAI) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. BTAI currently screens at market cap $36.1M.
Not investment advice. Open the ABT and BTAI stock pages for the full models.
Not investment advice.